Ameritas Investment Partners’s Cardiff Oncology CRDF Stock Holding History

Ameritas Investment Partners’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,678	Closed	-$9.2K	–	3203
2026 Q1	$9.2K	Hold	5,678	–	–	﹤0.01%	2889
2025 Q4	$16K	Hold	5,678	–	–	﹤0.01%	2745
2025 Q3	$11.7K	Buy	5,678 +1,840	+48%	+$5.08K	﹤0.01%	2905
2025 Q2	$12.1K	Hold	3,838	–	–	﹤0.01%	2911
2025 Q1	$12.1K	Hold	3,838	–	–	﹤0.01%	2758
2024 Q4	$16.7K	Hold	3,838	–	–	﹤0.01%	2707
2024 Q3	$10.2K	Hold	3,838	–	–	﹤0.01%	2909
2024 Q2	$8.52K	Buy	+3,838	New	+$14.5K	﹤0.01%	2970
2022 Q2	–	Sell	-2,835	Closed	-$7K	–	3097
2022 Q1	$7K	Hold	2,835	–	–	﹤0.01%	2888
2021 Q4	$17K	Hold	2,835	–	–	﹤0.01%	2706
2021 Q3	$19K	Hold	2,835	–	–	﹤0.01%	2724
2021 Q2	$19K	Buy	+2,835	New	+$24K	﹤0.01%	2758
2017 Q2	–	Sell	-26	Closed	-$2K	–	3005
2017 Q1	$2K	Buy	+26	New	+$3.53K	﹤0.01%	2918

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ameritas Investment Partners's CRDF Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 5,678 shares — an estimated $9.2K sold.

Ameritas Investment Partners first reported a position in CRDF in Q1 2017 and held it in 13 quarters. The position peaked at $19K in Q3 2021. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Ameritas Investment Partners reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
Ameritas Investment Partners sold 5,678 Cardiff Oncology shares in Q2 2026, an estimated $9.2K.
Ameritas Investment Partners first reported a position in Cardiff Oncology in Q1 2017 and held it in 13 quarters.
Ameritas Investment Partners's Cardiff Oncology position peaked at $19K in Q3 2021.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.